Paul R Womble1, Susan M Linsell1, Yuqing Gao1, Zaojun Ye1, James E Montie1, Tejal N Gandhi2, Brian R Lane3, Frank N Burks4, David C Miller5. 1. Department of Urology, University of Michigan, Ann Arbor, Michigan. 2. Division of Infectious Disease, University of Michigan, Ann Arbor, Michigan. 3. Department of Urology, Spectrum Health Medical Group, Grand Rapids, Michigan. 4. Department of Urology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan. 5. Department of Urology, University of Michigan, Ann Arbor, Michigan. Electronic address: dcmiller@med.umich.edu.
Abstract
PURPOSE: Recent data suggest that increasing rates of hospitalization after prostate biopsy are mainly due to infections from fluoroquinolone-resistant bacteria. We report the initial results of a statewide quality improvement intervention aimed at reducing infection related hospitalizations after transrectal prostate biopsy. MATERIALS AND METHODS: From March 2012 through May 2014 data on patient demographics, comorbidities, prophylactic antibiotics and post-biopsy complications were prospectively entered into an electronic registry by trained abstractors in 30 practices participating in the MUSIC. During this period each practice implemented one or both of the interventions aimed at addressing fluoroquinolone resistance, namely 1) use of rectal swab culture directed antibiotics or 2) augmented antibiotic prophylaxis with a second agent in addition to standard fluoroquinolone therapy. We identified all patients with an infection related hospitalization within 30 days after biopsy and validated these events with claims data for a subset of patients. We then compared the frequency of infection related hospitalizations before (5,028 biopsies) and after (4,087 biopsies) implementation of the quality improvement intervention. RESULTS: Overall the proportion of patients with infection related hospitalizations after prostate biopsy decreased by 53% from before to after implementation of the quality improvement intervention (1.19% before vs 0.56% after, p=0.002). Among post-implementation biopsies the rates of hospitalization were similar for patients receiving culture directed (0.47%) vs augmented (0.57%) prophylaxis. At a practice level the relative change in hospitalization rates varied from a 7.4% decrease to a 3.0% increase. Fourteen practices had no post-implementation hospitalizations. CONCLUSIONS: A statewide intervention aimed at addressing fluoroquinolone resistance reduced post-prostate biopsy infection related hospitalizations in Michigan by 53%.
PURPOSE: Recent data suggest that increasing rates of hospitalization after prostate biopsy are mainly due to infections from fluoroquinolone-resistant bacteria. We report the initial results of a statewide quality improvement intervention aimed at reducing infection related hospitalizations after transrectal prostate biopsy. MATERIALS AND METHODS: From March 2012 through May 2014 data on patient demographics, comorbidities, prophylactic antibiotics and post-biopsy complications were prospectively entered into an electronic registry by trained abstractors in 30 practices participating in the MUSIC. During this period each practice implemented one or both of the interventions aimed at addressing fluoroquinolone resistance, namely 1) use of rectal swab culture directed antibiotics or 2) augmented antibiotic prophylaxis with a second agent in addition to standard fluoroquinolone therapy. We identified all patients with an infection related hospitalization within 30 days after biopsy and validated these events with claims data for a subset of patients. We then compared the frequency of infection related hospitalizations before (5,028 biopsies) and after (4,087 biopsies) implementation of the quality improvement intervention. RESULTS: Overall the proportion of patients with infection related hospitalizations after prostate biopsy decreased by 53% from before to after implementation of the quality improvement intervention (1.19% before vs 0.56% after, p=0.002). Among post-implementation biopsies the rates of hospitalization were similar for patients receiving culture directed (0.47%) vs augmented (0.57%) prophylaxis. At a practice level the relative change in hospitalization rates varied from a 7.4% decrease to a 3.0% increase. Fourteen practices had no post-implementation hospitalizations. CONCLUSIONS: A statewide intervention aimed at addressing fluoroquinolone resistance reduced post-prostate biopsy infection related hospitalizations in Michigan by 53%.
Authors: Vassilios M Skouteris; E David Crawford; Vladimir Mouraviev; Paul Arangua; Marios Panagiotis Metsinis; Michael Skouteris; George Zacharopoulos; Nelson N Stone Journal: Rev Urol Date: 2018
Authors: Gregory B Auffenberg; Khurshid R Ghani; Shreyas Ramani; Etiowo Usoro; Brian Denton; Craig Rogers; Benjamin Stockton; David C Miller; Karandeep Singh Journal: Eur Urol Date: 2018-10-11 Impact factor: 20.096
Authors: Amy N Luckenbaugh; Gregory B Auffenberg; Scott R Hawken; Apoorv Dhir; Susan Linsell; Sanjeev Kaul; David C Miller Journal: J Urol Date: 2016-09-20 Impact factor: 7.450